178 replies to this topic

[caliban]

reg med business various

[ImmInst]

RegMed Sector News

[ImmInst]

Stem cell therapy for heart failure: two studies two successes
News-Medical.net - 21 hours ago

By Dr Ananya Mandal, MD The Center for Disease Control and Prevention says that heart failure affects nearly 6 million Americans leading to considerable risk of death, diminished quality of like ...

View the full article

[ImmInst]

As Geron Corporation (GERN) Exits Stem Cells, Who Will Be the Winners? NVIV, CUR, STEM
SmallCap Network - 25 minutes ago

Invivo Therapeutics Holdings (NVIV), Neuralstem (CUR) and StemCells (STEM) could benefit from Geron Corporation's (GERN) announced exit from the stem cell research market. By John Udovich Earlier ...

View the full article

[ImmInst]

NovaBay May Be In The Right Place At The Right Time With An Answer For Antibiotic Resistance
Seeking Alpha - 1 hour ago

Success for a small biotech or developing pharmaceutical company is often measured not only by the technology of its pipeline, but also by the ability of a company to position itself to be in the ...

View the full article

[ImmInst]

Insight: Stem cell therapy poised to come in from the cold
Reuters UK - 2 hours ago

Aastrom Biosciences Research Associate Judith Schmitt removes tissue culture and harvest solution from a centrifuge tube in the laboratory at their headquarters in Ann Arbor, Michigan November 29 ...

View the full article

[ImmInst]

California stem cell agency needs to study itself
Los Angeles Times - 2 hours ago

The California Institute for Regenerative Medicine has downplayed the recent exit from the stem cell field by Geron, but the fiasco raises questions about how the agency does business and whether ...

View the full article

[ImmInst]

NeoStem Might Be A Hidden Gem
Seeking Alpha - 2 hours ago

In the future, cell based medicine will hopefully be the standard of care for many serious medical conditions. Currently the potential may look a bit murky, with various degrees of successes and ...

View the full article

[ImmInst]

Osiris Shows No Reason To Invest In Stem Cell Ideas
Seeking Alpha - 25 minutes ago

The topic of whether stem-cell therapies are overhyped - OK, let me show my cards, the topic of just how overhyped they are - last came up around here in November, when Geron (GERN) announced that ...

View the full article

[ImmInst]

Pluristem Therapeutics (PSTI) On the Verge, BTX and ISCO Help Pull it Along
SmallCap Network - 3 minutes ago

By Bryan Murphy On the surface, it just looks like stem cell biotech stock Pluristem Therapeutics, Inc. (Nasdaq:PSTI) is stuck in the mud. Shares are currently trading at $2.66, down 4% for the ...

View the full article

[ImmInst]

InvestorStemCell.com : Is Validation of Regenerative Medicine Upon the World ...
Emailwire (press release) - 2 hours ago

A revolution in biotechnology is upon the world. It has been quietly playing out in labs across the world for decades. The paradigm shift in healthcare through regenerative medicine is here.

View the full article

[ImmInst]

The InVivo Effect
Seeking Alpha - 38 minutes ago

In 2011, when biotech Geron Corporation (GERN) halted its work and FDA-approved clinical trial on spinal cord research using human embryonic stem cells in patients, they left a gaping hole, confusion and disappointment for many investors and patients ...

View the full article

[ImmInst]

BioTime and Aastrom Biosciences -- Stem Cell Research Making Breakthroughs
Business Review USA (press release) - Mar 5, 2012

NEW YORK, NY--(Marketwire - Mar 5, 2012) - February was a challenging month for stem cell stocks. TickerSpy's Stem Cell Stocks Index (RXSTM) has slipped nearly 13 percent over the last month -- underperforming the S&P 500 by close to 17 percent over ...

View the full article

[ImmInst]

Abbott's New FreeStyle InsuLinx Receives FDA Clearance; Gilead, Pfizer and ...
BioMedReports (subscription) - Mar 9, 2012

By Staff and Wire Reports Below is a look at some of the headlines for companies that made news in the healthcare sector on March 8, 2012.

View the full article

[ImmInst]

Biotech Stocks Look to Benefit From JOBS Act
MarketWatch (press release) - 9 hours ago

NEW YORK, NY, Apr 10, 2012 (MARKETWIRE via COMTEX) -- One major problems in recent years for emerging biotech companies has been funding for research.

View the full article

[ImmInst]

NeurogesX Shares Soar On FDA Decision (PCYC, WBMD, NGSX, TEAR, CYTX, BTX)
Retirement Planning - 2 hours ago

By Scott Sheffield Pharmacyclics Inc (NASDAQ:PCYC) climbed up 2.86% to $26.60. So far this year, the stock is up over 79%. The 52-week range for the stock is $5.62 and $29.43.

View the full article

[ImmInst]

MAP Pharmaceuticals Provides Update on LEVADEX; Impax Confirms Patent ...
BioMedReports (subscription) - 11 hours ago

By Staff and Wire Reports Below is a look at some of the headlines for companies that made news in the healthcare sector on April 12, 2012.

View the full article

[ImmInst]

RegMed Competitive and Market Intelligence 4/13/12, throw some salt over your ...
Proactive Investors USA & Canada - 2 hours ago

Today's Gospel: Looking at this end of week, so far … I reiterate … we're going to see more … irregularity in … RegMed universe gyrations as we move into the spring through the summer lull … hopefully, positive sentiment MIGHT start to appear but, ...

View the full article

[ImmInst]

Update on HyQ Biologics License Application; Vermillion Receives Notice of ...
BioMedReports (subscription) - 59 minutes ago

By Staff and Wire Reports Below is a look at some of the headlines for companies that made news in the healthcare sector on April 16, 2012.

View the full article

[ImmInst]

Ruling in Texas Could Provide New Opportunities for Stem Cell Companies
Marketwire (press release) - Apr 16, 2012

NEW YORK, NY--(Marketwire - Apr 16, 2012) - March has shown to be a troublesome month for stem cell stocks. TickerSpy's Stem Cell Stocks Index (RXSTM) has fallen over 16 percent in the last month, in comparison the SPDR S&P Biotech (ETF) has fallen ...

View the full article

[ImmInst]

Roche Decides Not to Extend its Offer For Illumina; Vertex Advances Goal of ...
BioMedReports (subscription) - 1 hour ago

By Staff and Wire Reports Below is a look at some of the headlines for companies that made news in the healthcare sector on April 18, 2012.

View the full article

[ImmInst]

Neostem: Investing In The Potential Success Of Cell Therapy
Seeking Alpha - 2 hours ago

Over the last several months I have taken a particular interest in cancer stem cell therapies. The primary reason for my interest has been great results from a large number of candidates that are testing the boundaries of cancer treatment, ...

View the full article

[ImmInst]

Neostem: Investing In The Potential Success Of Cell Therapy
Seeking Alpha - Apr 23, 2012

Over the last several months I have taken a particular interest in cancer stem cell therapies. The primary reason for my interest has been great results from a large number of candidates that are testing the boundaries of cancer treatment, ...

View the full article

[ImmInst]

Stem Cell Research: Which Companies Will Emerge As Frontrunners?
Seeking Alpha - Apr 19, 2012

Advances in modern medicine have been significant as scientists fight to prevent and cure the hosts of injuries and diseases plaguing mankind.

View the full article

[ImmInst]

Neostem's Comeback In The Making
Seeking Alpha - 31 minutes ago

As an investor I am always looking for opportunities. In my family there are several people who have a medical background and sometimes you have conversations about biotech investing.

View the full article

[ImmInst]

NeoStem: Huge Potential In The Cell Therapy Sector
Seeking Alpha - 3 hours ago

As the cell therapy sector starts growing, it gains the attention of institutional investors, although it's known as a risky venture.

View the full article

[ImmInst]

RegMed Competitive and Market Intelligence 5/2/12, has the toothpaste run out ...
Proactive Investors USA & Canada - May 2, 2012

Today's Gospel: RegMed stocks opened lower and still bouncing mid-day, Wednesday … share pricing is flatter in thin trading with the NASDAQ barely up … with, few leader(s) … little green (ups) and equal red (downs) and 3 black (flats) on the screen.

View the full article

[ImmInst]

NeoStem (NYSEAMEX:NBS): A Key Player in Stem Cell Research
Market Playground - May 4, 2012

By Dutch Trader As an investor I am always searching to find the next “big thing”. Looking for that company that is developing a technology that will revolutionize its industry.

View the full article

[ImmInst]

Aastrom to Present Results of Phase 2a Clinical Trial of Ixmyelocel-T in ...
MarketWatch (press release) - 5 hours ago

ANN ARBOR, Mich., May 7, 2012 (GlobeNewswire via COMTEX) -- Aastrom Biosciences, Inc. (UTD:ASTM) , the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced ...

Aastrom To Present Results Of Phase 2a Clinical Trial Of Ixmyelocel-T - NASDAQ

View the full article

[ImmInst]

Aastrom to Present Results of Phase 2a Clinical Trial of Ixmyelocel-T in ...
MarketWatch (press release) - 9 hours ago

ANN ARBOR, Mich., May 7, 2012 (GlobeNewswire via COMTEX) -- Aastrom Biosciences, Inc. (UTD:ASTM) , the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced ...

Aastrom To Present Results Of Phase 2a Clinical Trial Of Ixmyelocel-T - NASDAQ

View the full article